Skip to main content

James Crowe Jr.

Caucus explores crucial role of NIH research funding

Dec. 3, 2015—James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center, and Anthony Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), recently participated in a U.S. Senate National Institutes of Health (NIH) caucus briefing held in Washington, D.C., by Senate NIH caucus co-chairs Sens. Lindsey Graham (R-SC) and Dick Durbin (D-IL).

Read more


Two Ebola Survivors’ Blood Could Help Vanderbilt Researchers Find A Treatment

Oct. 19, 2015—Vanderbilt researchers could be one step closer to finding a way to fight the deadly Ebola virus – thanks to two Ebola victims from Nigeria, who faced death and survived. Vanderbilt researchers developed a unique method of isolating potent Ebola-fighting antibodies from survivors’ blood and they believe these newest potent antibody samples are an important...

Read more


Survivors of Ebola outbreak take part in VUMC vaccine study

Sep. 24, 2015—Two survivors of a 2014 Ebola outbreak in Nigeria visited Vanderbilt University Medical Center last week to share their experiences and participate in a study aimed at finding ways to treat the often-fatal infection.

Read more


Ebola symposium to feature Nigerian physicians

Sep. 10, 2015—Three Nigerian physicians who survived Ebola virus disease in July 2014 after coming in direct contact with an Ebola-infected patient will speak at Vanderbilt University Medical Center next Wednesday, Sept. 16.

Read more


How to trick a wily virus

Jul. 24, 2015—Vanderbilt investigators have discovered how human antibodies induced during testing of an experimental “bird flu” vaccine kill the virus.

Read more


Study could lead to vaccine for mosquito-borne dengue virus

Jul. 9, 2015—Researchers at Vanderbilt University and the National University of Singapore have determined the structure of a human monoclonal antibody which, in an animal model, strongly neutralizes a type of the potentially lethal dengue virus.

Read more


Vanderbilt researchers develop potential treatment to fight mosquito-borne chikungunya virus

Jul. 8, 2015—In late 2013 the Caribbean had its first case of the mosquito-borne chikungunya virus. Today there have been almost 1.2 million cases in 44 countries or territories, including 177 cases in 31 U.S. States.

Read more


‘Redesigned’ antibodies may control HIV: study

May. 21, 2015—With the help of a computer program called “Rosetta,” researchers at Vanderbilt University have “redesigned” an antibody that has increased potency and can neutralize more strains of the AIDS-causing human immunodeficiency virus (HIV) than can any known natural antibody.

Read more


VU lands $9 million NIH grant to design better flu vaccines

May. 15, 2015—Vanderbilt University researchers have received a five-year, $9 million grant from the National Institutes of Health (NIH) to design more effective flu vaccines and novel antibody therapies.

Read more


VU joins national effort to speed Ebola therapy testing

Apr. 8, 2015—Vanderbilt University researchers have joined a multi-center effort led by Pennsylvania-based Inovio Pharmaceuticals Inc. to accelerate development of potential antibody therapies against the often-lethal Ebola virus.

Read more


Studies show human antibodies can fight lethal Marburg virus

Feb. 26, 2015—Researchers at Vanderbilt University, the University of Texas Medical Branch at Galveston and The Scripps Research Institute for the first time have shown how human antibodies can neutralize the Marburg virus, a close cousin to Ebola.

Read more


Core facilities key driver of VUMC research gains

Jan. 29, 2015—During the past five years, Vanderbilt University Medical Center has become a leader in “personalized medicine,” the use of genomic information to individualize patient care.

Read more


VIEW MORE EVENTS >